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Background  
        Sickle cell disease (SCD) is the most common inherited blood disorder in the United 
States. As SCD can cause significant morbidity and decrease in life expectancy, further 
research on curative options is of great interest. Hematopoietic stem cell transplant 
(HSCT) is the only treatment option offering a chance of cure, but the risks of treatment 
are not negligible. Because the outcomes of HSCT are best when the procedure is 
performed at a younger age, understanding what parents know about transplant, their 
opinion on this option and the risks they are willing to take to achieve a cure is of great 
value. As sickle cell disease has changed in the United States from a life-threatening 
condition of childhood to a chronic condition with most of the burden of morbidity and 
mortality shifted towards adulthood, it is necessary for parents to be fully aware of long 
term risks and educated on all therapeutic options, so the optimal decision can be made. 
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Objectives  
        (i) To learn about parents’ recollection and pursuit of further information after 
undergoing an educational session on risks and benefits of HSCT. (ii) To learn about 
their worries about transplant and the highest mortality and infertility risks they are 
willing to accept in order to achieve a cure for their child. (iii) To learn about parents’ 
readiness to proceed to transplant based on a hypothetical scenario.  
Methods                                                                                                                                                         
This project was performed as part of an ongoing prospective, observational study in 
which parents were approached for an educational session and a series of surveys, during 
their child’s routine visits to the Pediatric Hematology Clinic at Boston Medical Center. 
Subjects were parents or guardians of children with SCD under the age of twenty-one. 
All subjects answered an anonymous baseline questionnaire and underwent a 
standardized educational session on the role, benefits and risks of stem cell transplant. 
Those who provided informed consent completed a post-encounter questionnaire on their 
perceptions about transplant and a follow-up questionnaire. The aims of this study were 
met by design and administration of the follow-up questionnaire; which consisted of 11 
open and close-ended questions administered over the phone, 14 to 30 months after 
completion of the educational session.  
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Results   
      Thirty-five parents had been previously enrolled in the study and 26 of these (74%) 
responded to the follow-up questionnaire. Two subjects actively declined participation 
and 7 passively declined participation by repeated claim of unavailability. The risk of 
death that parents were willing to accept ranged from 0 to 50%. Thirteen were not willing 
to accept any risk, seven were able to accept a 5% risk, three a 10% risk, one a 20% risk 
and two a 50% risk. The risk of infertility that parents were willing to accept ranged from 
0 to 100%. Three were not willing to accept any risk of infertility, five were able to 
accept a 5% risk, seven a 10% risk, one a 15% risk, two each for 20%, 25%  and 50% and 
four 100%. Nine parents worried most about death, while another nine worried most 
about the transplant not working. Two stated infertility, one said graft-versus-host disease 
and five were most concerned about the recovery process. For the option of proceeding to 
transplant (based on a hypothetical scenario), nineteen parents (73%) were willing to 
accept the risk now; five would decline the offer and two were undecided and unable to 
answer.  
Conclusions: Stem cell transplant is often performed on children for treating sickle cell 
disease, which creates importance for educating parents and understanding their 
concerns. Parents were willing to accept higher risks of death and infertility as a child’s 
severity of disease increased. Families of children from all disease severities chose to 
accept transplant in a hypothetical scenario. Physicians may introduce transplant to all 
SCD families as opposed to viewing this option as a last resort.  
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INTRODUCTION 
 
Sickle cell disease (SCD) is the most common inherited blood disorder in the 
United States. It occurs most frequently in African-Americans, but has prevalence as high 
as 30% in some countries (Ender, 2011). As SCD can cause morbidity and decrease in 
life expectancy, further research on curative options is of great interest.  Hematologic 
stem cell transplant (HSCT) is the only treatment option offering a chance of cure, but the 
risks of treatment are not negligible (Bernaudin, 2009). Because the outcomes of HSCT 
are best when the procedure is performed at a younger age, understanding what parents 
know about transplant, how they feel about this option and the risks they are willing to 
take to achieve a cure is of great value. It is also necessary to understand what type of 
information parents retain and whether education changes their short or long-term 
perceptions.  
To analyze what factors influence parents’ perceptions, this introduction will 
review the pathophysiology, inheritance, prevalence, complications and treatment options 
for SCD. It will also provide a framework and justification for the study, which will 
contribute to improved understanding of parental awareness of HSCT’s risks and 
benefits, parental willingness to take risk to achieve a cure and their readiness to proceed 
to transplant.   
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Pathophysiology:  
       Sickle cell disease is marked by defective hemoglobin. Hemoglobin is the iron-
containing oxygen-transport metalloprotein found in red cells of vertebrates and other 
animals. In mammals, the protein is approximately ninety-seven percent of the cell’s dry 
content and about thirty-five percent of the total content. Hemoglobin transports oxygen 
from the lungs to the rest of the body, where it is released. The protein molecule has a 
tetrameric structure, which consists of two alpha and two beta subunits that are held 
together by non-covalent interactions (Williams, 2010). In sickle cell anemia, however, 
there is a point mutation in the beta-globin chain (Figure 1). The amino acid glutamic 
acid is replaced by the less polar amino acid valine at the sixth position of the beta chain. 
This mutation favors a hydrophobic interaction between each strand and its neighbor. 
Thus, the abnormal hemoglobin becomes less soluble and polymerizes into crystals that 
distort the red blood cells into a sickle shape (O’Brien, 2010).  
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Figure 1: Amino Acid Chains For Normal and Sickle Cell Disease Hemoglobin 
 
The chain of colored boxes represent the first eight amino acids in the beta chain of hemoglobin. 
The sixth position in the normal beta chain has glutamic acid, while sickle beta chain has valine. 
This is the sole difference between the two. Available from: 
http://sickle.bwh.harvard.edu/scd_background.html.  Accessed on March 14, 2012.                                                                
 
Normal red blood cells are elastic, allowing them to flow through blood vessels. Unlike 
normal red blood cells, red blood cells with sickle hemoglobin (sickle cells) assume the 
shape of a sickle or crescent when oxygen levels are low. This finding is due to 
precipitation of the polymerized hemoglobin molecule within the cell (Hsieh, 2009). 
Once sickle cells assume the crescent shape they become less elastic and can either break 
(in capillaries or the spleen) and release their contents or block small veins and capillaries 
and prevent adequate oxygen delivery to tissues (Gazaiev, 2011). 
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      Obstruction of small capillaries causes decreased oxygen delivery to the organ, 
inflammation, and pain. Over time, tissues are increasingly damaged, which can lead to 
organ dysfunction in any organ, but typically in the lungs, spleen, kidneys, bone, retina, 
and brain. If sickle cells become lodged and break down, they release their heme products 
into the bloodstream and cause jaundice, a classic finding in SCD (Gupta, 2010).  
       Due to their fragility, sickle cells have a shortened life span lasting from ten to 
twenty days. In contrast, normal red blood cells survive for approximately one hundred 
and twenty days. Sickle cells’ decreased life span causes an insufficient supply of red 
blood cells, resulting in anemia. Acute anemia can cause fatigue or shortness of breath 
upon exertion (Buchanan, 2010). Chronic anemia of sickle cell disease, however, can 
cause multi-organ dysfunction.  
Inheritance: 
      Sickle cell disease follows an autosomic recessive inheritance, meaning a person must 
inherit two copies of the sickle cell gene, one from each parent. The HBB gene codes for 
hemoglobin and is located at position 15.5 on chromosome 11. Mutations in this gene 
produce various hemoglobin variants. Some of these variants maintain normal function; 
however, the majority of them produce disease states. When a person is heterozygous for 
the mutation (inheritance of one sickle cell gene), their condition is called sickle cell trait. 
People with sickle trait generally have no symptoms, lead normal lives and are thought to 
be more tolerant of the malaria infection (Hsieh, 2009). This form of the disease, 
however, is hereditary. Other forms include sickle hemoglobin C disease (HbSC) and 
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sickle beta plus thalassaemia (HbSB+).These forms are heterozygous states in which one 
mutated allele creates abnormal hemoglobin S and the other allele creates another form of 
abnormal hemoglobin. Each of these other genotypes has a slightly varied clinical 
phenotype (Vermylen, 1997).  
Prevalence: 
       Sickle cell disease is present mainly in the African-American population and is found 
with less frequency in the eastern Mediterranean and Middle East populations. The sickle 
cell gene is present in eight percent of black Americans with more than seventy thousand 
people in the Unites States having SCD. However, sickle cell trait has prevalence as high 
as thirty percent in several African countries. Although hematologic changes are evident 
in the first few weeks of life and the disease can be diagnosed by newborn screen, clinical 
manifestations are often not seen until the second half of the first year of life (Ender, 
2011). By this time, in the absence of normal adult hemoglobin, the fetal hemoglobin 
(Hb-F) has sufficiently decreased for Hb-S to express itself. Children with SCD 
experience a variable clinical course, ranging from asymptomatic, to mild infrequent pain 
crises, to chronic, severe and debilitating pain, restrictive lung disease, growth restriction 
and stroke. Other complications, more often seen in adolescents and adults include leg 
ulcers, osteonecrosis, gallstones, renal failure, and retinal damage. Life expectancy is 
decreased compared to the general population, with an average life span into the mid to 
late forties (Fry, 2010). 
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Treatment: 
        Most treatments and interventions (medications, transfusions, surgeries), can only 
assist with lessening of acute and chronic symptoms or with reducing the risk of some 
complications. Hematopoietic stem cell transplant (HSCT) is currently the only curative 
treatment for SCD (Gaizev, 2005). HSCT, however, is not a risk-free intervention and the 
decision to proceed to transplant must incorporate the parent’s preferences and 
willingness to accept risks for a chance of cure.  
Pain-Relieving Medications 
     Pain medications, such as non-steroidal anti-inflammatory agents and narcotics, along 
with adequate hydration and avoiding extremes in temperature play a major role in 
preventive and symptomatic relief of pain (Gaizev, 2005). Patients with SCD usually 
have a home pain management plan, but patients can require intermittent hospitalizations 
for acute pain.  
Hemoglobin-F Increasing Medications  
       Hydroxyurea is the only medication available for SCD reduction of symptoms. It is 
most frequently prescribed to patients with moderate-to-severe disease as characterized 
by frequency and intensity of pain crises and history of acute chest syndrome. 
Hydroxyurea works by increasing the amount of fetal hemoglobin. Fetal hemoglobin is 
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the main hemoglobin present in fetuses and infants and generally disappears by six 
months of age (Kaye, 1996). The presence of fetal hemoglobin in a red cell containing 
sickle hemoglobin prevents sickling of the red blood cell by interfering with the 
hydrophobic interactions that tend to occur between sickle hemoglobins and therefore, by 
reducing polymerization of sickle hemoglobin inside the cell (Wynn, 2009).  
        Hemoglobin F has higher affinity for oxygen than hemoglobin B or S (Figure 2). 
This phenomenon occurs, because fetal hemoglobin must be oxygenated in the placenta, 
where the oxygen partial pressure (pO2) is lower than in the lungs. The higher affinity of 
fetal hemoglobin is due to its lower affinity for bisphosphoglycerate (BPG). Once fetal 
hemoglobin undergoes its normal decline by 6 months of age, the proportion of sickle 
hemoglobin increases and symptoms arise (Van Besien, 2010). Children and adults with 
elevated levels of fetal hemoglobin, either from treatment with hydroxyurea or due to 
persistent activation of the hemoglobin F gene, tend to have milder symptoms than their 
peers.  
       Although hydroxyurea is generally considered to be safe and can be taken 
indefinitely, not every patient achieves the full benefit. Some patients do not respond to 
hydroxyurea, while others have side effects consisting of nausea, constipation and 
drowsiness, neutropenia or thrombocytopenia (low neutrophil count and low platelet 
count, respectively) (Walters, 2010).  
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Figure 2. Oxygen Bonding of Fetal Hemoglobin versus Adult Hemoglobin                                    
Fetal hemoglobin differs from adult hemoglobin in that it is able to bind oxygen with 
greater affinity than the adult form. This gives the developing fetus better access to 
oxygen from the mother’s bloodstream.  Available from: http://faculty.ucc.edu/biology-
potter/mechanics_of_breathing.htm.   Accessed on March 18, 2012.  
 
 
Blood Transfusions  
       Blood transfusions play a central role in the management of sickle cell disease. 
Episodic transfusions are critical for treatment of acute complications such as acute chest 
syndrome, hypersplenism, and stroke. Chronic (monthly) transfusions are used for 
prevention of stroke.  Monthly transfusions aid in improving height and weight for 
children with sickle cell disease. Transfusions, however, have short term and long term 
risks, such as hyperviscosity, immune reaction, and iron overload (Davies, 1997). 
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Nitric Oxide 
Acute management and prevention of vaso-occlussive crises (pain crises) is of 
great interest. Research has focused on nitric oxide, a natural chemical produced in the 
body that relaxes smooth muscles and expands blood vessels. Patients with sickle cell 
disease are deficient in nitric oxide. This lack of nitric oxide constricts blood vessels and 
it thought to causes pain in sickle cell disease (Griffths, 2005). Several studies suggest 
that inhalation of nitric oxide deceases the severity and frequency of sickle cell crises.  
In a study by Fry et al. 2010, the investigators wanted to determine how children 
with sickle cell disease responded to nitric oxide and whether this treatment lessened 
symptoms. The researchers found that nitric oxide was effective by decreasing the 
severity and frequency of pain episodes. 
Another study by Griffths et al. 2005, studied whether inhalation of nitric oxide 
reduced crisis pain in adult patients and the safety of inhaled nitric oxide. This study 
demonstrated that inhaled nitric oxide significantly reduced pain scores compared to 
placebo. Morphine use for pain was also lower in the inhaled nitric oxide group.  
A third study by Jordan et al. 2011, examined nitric oxide’s effect on acute 
respiratory distress syndrome. They found that nitric oxide lessened the duration for 
pressure controlled mechanical ventilation and hospitalization stay.  
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         There is interest in arginine supplements as possible treatment for sickle cell 
disease. Arginine contributes to the production of nitric oxide and the prevention of 
pulmonary hypertension. There is also much interest in preventing red blood cell 
dehydration (Bernaudin, 2005). Sickle cells’ crescent shape cause them to lose volume 
and develop localized increases of intracellular calcium. This calcium activates the 
membrane protein Gardos channel, which helps to maintain erythrocyte potassium levels. 
Once activated, the Gardos channel leaks potassium into the plasma. Water then leaves 
the cell, resulting in erythrocyte dehydration. This dehydration increases the hemoglobin 
S concentration, leading to further sickling of red blood cells. Several mineral 
supplements, such as magnesium pidolate and zinc sulfate, may prevent potassium loss 
and red blood cell dehydration (Gupta, 2010).   
Antibiotics   
        Antibiotics prevent infections in infants with sickle cell disease. Children with sickle 
cell anemia are highly susceptible to infections due to splenic autoinfarction. Functional 
asplenia makes patients vulnerable to infections with encapsulated organisms, such as 
Streptococcus pneumonia and Hemophilus influenzae (Gaizev, 2005). Additionally, some 
studies suggest that neutrophils do not function properly in patients with sickle cell 
disease.  
       Neutrophils are the most abundant type of white blood cell in mammals and are part 
of the innate immune system. In a study by Rehman et al. 1996, investigators evaluated 
whether impaired neutrophils may play a role in the pathogenesis of vasocclusive crises. 
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Results showed that impaired neutrophils from sickle cell patients showed dysregulated 
L-selectin shedding and increased H2O2 production. These impairments were able to 
immobilize neutrophils on the endothelium, thereby reducing blood flow and allowing 
microvascular occlusion and vascular damage. In a study by Wynn et al. 2009, 
researchers found a significant difference in neutrophil activation between sickle cell 
patients and healthy controls as indicated by decreased L-selectin expression, enhanced 
expression of CD64 and increased levels of soluble markers like elastase. The conclusion 
was that impaired neutrophils played a large role in the initiation and propagation of 
vaso-occlusive crises.  
        In reaction to these findings, established guidelines recommend that children with 
sickle cell disease begin taking prophylactic antibiotics at two months of age and 
continue until five years (Bernaudin, 2005). Penicillins are the antibiotic of choice for 
this prophylaxis, and implementation of these guidelines, along with immunizations, has 
significantly decreased mortality of children with sickle cell disease in the first five years 
of life.  
Surgical Interventions  
        There is no surgical cure for sickle cell disease; however, surgery is used to treat 
certain sickle cell disease complications. Splenctomy, the removal of the spleen, is used 
to treat splenic sequestration, which can cause hemodynamic instability and death from 
trapping of red blood cells in the spleen. Cholecystectomy, the removal of the 
gallbladder, is used to prevent or treat problems caused by gallstones. Urologic 
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procedures are performed to resolve priapism, a persistent, painful erection of the penis 
unrelated to sexual desire. If left untreated, priaprism can lead to permanent erectile 
dysfunction and penile necrosis. Hip replacement is performed in response to 
osteonecrosis, the break down and death of bone tissue due to insufficient blood supply 
(Davies, 1997).  
Hematopoietic Stem Cell Transplant 
        Hematologic stem cell transplant (HSCT) is the only potential curative treatment 
option; however, the risks of treatment are not negligible. The first transplant for SCD 
was reported in 1984 when a subject with leukemia and SCD was cured of both diseases 
after undergoing HSCT for treatment of leukemia (Hsieh, 2009).  
The Procedure: The bone marrow is the substance in the center of the bones, which hosts 
the hematologic stem cells and produces red blood cells, white blood cells and platelets, 
among other blood and immune cells. By undergoing a bone marrow transplant, the 
person is treated with high dose chemotherapy to destroy his/her bone marrow stem cells. 
The person then receives donated bone marrow stem cells from a closely matched donor 
through injection into a vein. Over time the donor’s stem cells grow in the recipient’s 
bone marrow, thus allowing for the production of normal hemoglobin (Bernaudin, 2009). 
The Donors: Full siblings are the preferred donors, but the chance of being a match is 
only about twenty-five percent for each sibling. If there is no sibling or sibling that is a 
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genetic match, the person can receive stem cells from a matched donor found in the 
National Marrow Donor Program.  
The Criteria: The criteria to proceed with HSCT in SCD are currently a moving target. In 
the Unites States, HSCT is mostly considered for children younger than sixteen, who 
have an available donor, no significant damage to major organs and have experienced or 
are determined to be at risk for severe SCD complications. Some of the complications of 
interest include risk of stroke, recurrent acute chest syndrome and high frequency of pain 
crises. The most widely accepted criteria were published by Walters, et al in 1996, and 
are displayed in Figure 3.  In the absence of these complications physicians often seek 
other treatment alternatives as transplant has its own serious risks. However, in Europe, 
consideration is underway to recommend HSCT for all children with SCD who have a 
sibling who is a match (Walters, 1996).  
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Figure 3. Published criteria for proceeding to HSCT in patients with SCT. Table 
taken from Walters, et al in 1996.  
 
The Risks: The risks of HSCT are broad but include graft failure, death, sepsis, infertility, 
graft-versus-host-disease and mixed chimerism. Graft failure occurs when the 
transplanted stem cells fail to grow in the recipient’s bone marrow. Death can occur from 
toxicity of the high dose chemotherapy but also from infections and other events. The 
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risk of death from sibling-matched HSCT is likely 5-15%. However, European case-
series in which children with mild to no symptoms went through HSCT, showed 100% 
survival (Brown, 2011). Sepsis and death from infection can occur after destruction of  
the patient’s bone marrow, because he/she has insufficient white blood cells and therefore 
compromised immunity.  
Graft-versus-host disease (GVHD) is an inflammatory disease in which there is 
attack of the new bone marrow’s immune cells against the recipient tissues. This disease 
can occur despite the donor and recipient being HLA-identical, because the immune cells 
recognize other differences in the tissues. Acute GVHD usually occurs within the first 
three months after transplant. Chronic GVHD occurs after the first three months of 
transplant and can last a lifetime. Rates of GVHD vary between thirty to forty percent for 
related donors and sixty to eighty percent for unrelated donors (Buchanan, 2010). Mixed 
chimerism is the coexistence of donor and recipient hematopoietic cells, resulting in the 
variable presence of normal hemoglobin and hemoglobin S in the recipient’s blood 
(Boncimino, 2010). 
Parents’ Opinions: Few studies have addressed parental attitudes regarding the use of 
HSCT as a treatment option for SCD. In a study by Kodish et al. 1991, researchers 
assessed parental attitudes on bone marrow transplant mortality risk. After briefly 
describing bone marrow transplant and graft-versus-host disease to parents, the study 
investigators presented a series of hypothetical situations. The result was that 36 of 67 
(47%) parents were willing to accept some risk of short-term mortality. A total of 25 of 
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67 (37%) parents were willing to accept the current 15% mortality risk, and 8 of 67 
(12%) were willing to accept a mortality risk of 50% or more. Only 9 of 67 (13%) stated 
that they would accept a 15% or more mortality risk and an additional 15% risk of 
GVHD. The parents’ decisions were not related to the clinical severity of their child’s 
illness (Kodish, 1991). Although this study examined familial attitudes about mortality 
risk, it is unclear if these attitudes have changed since the study’s occurrence in 1991. 
The study also did not examine parental knowledge of bone marrow transplant at the start 
of the study and whether attitudes changed afterwards.  
A study by Walters et al. 2010 indicated that parental refusal accounts for 9.5% of 
reasons for not proceeding to transplant. For patients less than 16 years of age who met 
study protocol criteria, only 41% agreed to have HLA typing. Of those who agreed to be 
HLA typed, 57% underwent transplant. These results indicate parents’ initial 
apprehensiveness about transplant but their increased comfort level as they learn more 
about the procedure.  
Many parents understand little science about stem cell transplant. Therefore, 
investigation is needed to see what parents currently think about the procedure, what risks 
they are willing to accept and what they would like to know more about. Parental 
concerns must be efficiently addressed since child’s age plays an important role in 
determining who fits inclusion criteria. Thus, the goal of the overlying project being 
conducted at Boston Medical Center was to educate parents on transplant’s curative 
potential, assess what parents understand about curative treatment and obtain information 
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on their most common concerns and worries. The purpose of the follow-up questionnaire 
was to learn if knowledge motivated parents to learn more about transplant, what 
continued to worry them about transplant, the risk they were willing to take for cure and 
their readiness for transplant, based on a hypothetical scenario.  .  
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                                                         SPECIFIC AIMS 
Sickle cell disease (SCD) can have a variable and unpredictable clinical course. 
Although mortality in childhood has decreased, the morbidity and early mortality for 
adults with SCD remains noteworthy (Bernaudin, 2005). The use of hematopoietic bone 
marrow transplant (HSCT) as a therapeutic approach shows great promise but also 
presents many ethical and clinical dilemmas. Studies suggest that outcomes after HSCT 
are best when the procedure is done at a younger age, particularly in childhood, thus the 
burden of the decision-making falls on the parent(s) of children. Literature on parental 
understanding and attitudes towards HSCT is limited. A study to address this knowledge 
gap has been underway at the Pediatric Hematology Clinic at Boston Medical Center 
since 2009. The current study entailed a follow-up survey and had the following aims: 
(i) To learn about parents’ recollection and pursuit of further information after 
undergoing an educational session on risks and benefits of HSCT 
(ii) To learn about their worries concerning transplant and the highest mortality 
and infertility risks parents are willing to accept in order to achieve a cure for 
their child 
(iii) To learn about parent’s readiness to proceed to transplant based on a 
hypothetical scenario 
19 
 
                                                         METHODS 
This project was performed as part of an ongoing prospective, observational study 
in which parents were approached for an educational session and a series of surveys, 
during their child’s routine visits to the Pediatric Hematology Clinic at Boston Medical 
Center. Subjects were parents or guardians of children with SCD under the age of twenty-
one. All subjects answered an anonymous baseline questionnaire and underwent a 
standardized educational session on the role, benefits, and risks of stem cell transplant. 
Those who provided informed consent completed a post-encounter questionnaire on their 
perceptions about transplant and a follow-up questionnaire. The aims of this study were 
met by design and administration of a follow-up questionnaire.  
Study Design 
Because little is known about parental attitudes toward HSCT, an exploratory and 
qualitative research strategy was considered to be most appropriate and used.  
Target Population  
Subjects were parents of children with SCD who had previously consented to the 
educational study being conducted at Pediatric Hematology Clinic at Boston Medical 
Center on parental awareness and interest in HSCT for their children with SCD.  
Inclusion criteria for this study had been child’s age <21 years, diagnosis of SCD of the 
HbSS, HbSC or HbSB+ and arrival to clinic for a routine or “well child” visit.          
Verification of child’s sickle cell disease type and clinical course was performed through 
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a medical record review. This review recorded baseline medical data, including white 
blood cell count, hemoglobin, reticulocyte count, bilirubin, LDH and creatinine and 
whether the child was prescribed any narcotics or hydroxyurea for home use. Study 
investigators obtained information on history of stroke, acute chest syndrome, pain crises, 
abnormal MRI and past hospital admits.  
Survey Design  
Every effort was made to design a clear and easily understood phone follow-up 
questionnaire (Appendix 2). This questionnaire used sixth-grade language and gave the 
option of access to an interpreter in order to ensure families’ complete understanding. 
The survey avoids any jargon and double negatives. Questions were designed to be short, 
used simple language and follow a similar format to the rest of the questions. The goal of 
this format was to improve predictability and for parents to become more comfortable 
with answering questions as they moved through the questionnaire. Seven of the ten 
questions were “yes/no”, but always included the option “I don’t know”. These numbers 
were coded, using 0 = “no” or “I don’t know” and 1 = “yes”. Each yes/no question 
included examples in order to avoid any recall bias. These close-ended questions allowed 
the subject to focus on certain choices, ensure that he/she considered each possibility and 
allowed for more direct route to quantitative statistical results.  Numerical answer choices 
did not contain overlapping numbers, in order to reduce misclassification (the possibility 
of being put in the wrong study category).  
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Conducting the Survey 
The follow-up questionnaire was administered over the phone to subjects enrolled 
in the parent study 14 to 30 months after the date of enrollment. Parents were phoned 
three times during business hours with alternate times if needed. If parent did not answer 
phone or did not complete questionnaire after three attempts, their response was assumed 
to be passive refusal. All questions and statements guiding the subject through the 
questionnaire were fully written out. This layout provided the caller with a standard 
format to complete each interview. Each question was asked one at a time and referred to 
parents’ knowledge or attitudes since their last appointment. For the three open-ended 
questions, parents were able to give a range of answers but were encouraged to narrow 
them down to one. These questions allowed parents more opportunity to share their 
personal experiences and to state what the research team did not consider. For all ten 
questions, potentially ambiguous terms were discussed and clear explanations were 
available and standardized. 
Ethical Considerations 
The principal investigator and study staff were sensitive to patient confidentiality 
and aware of patient rights. The project for baseline and parents’ perspective 
questionnaires was approved by the Boston Medical Center Institutional Review Board 
(BMC IRB) in the summer of 2009.The follow-up questionnaire was submitted to the 
BMC IRB in summer 2011 and approved on August 19, 2011. All data was de-identified, 
and only the investigator and study staff had access to this material. All data was 
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password protected and saved in the principal investigator’s computer under restricted 
access. Information will be saved until completion of data analysis and publication.  
Data Analysis  
Data organized through Excel spreadsheets. Frequencies and proportions were 
calculated and organized in tabular form to present the full cohort and compare parents’ 
responses with their perceived child’s severity of disease. For open-ended questions, the 
study team maintained a record of all responses. The follow-up questionnaire was 
analyzed against the parents’ perspective questionnaire to find any change in the 
percentage of responses. The parent’s perspective questionnaire is one of the tools used in 
the overall study and is available in the attachments for reference. Due to the small 
sample size and qualitative nature of this research study, testing for statistical 
significance was not pursued.  
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                                                           RESULTS 
Of the 35 subjects enrolled in the overall study twenty-six (74%) responded to the 
follow-up questionnaire. All subjects are referred to as parents. Their children included 
14 girls and 12 boys with SCD. As seen in Table 2, the children ranged from 9 months to 
18 years. Two parents declined to complete the follow-up questionnaire, and seven 
passively refused through continued unavailability after three phone attempts. Of the 
children, whose parents responded to the survey twenty-one had Hb-SS sickle cell 
disease, four had Hb-SC disease and one child had HB-SB+ disease. Furthermore, based 
on parents’ responses to the baseline questionnaire, none of the children had any 
symptoms, 12 had mild symptoms, 12 had moderate symptoms and 1 had severe 
symptoms. One parent did not record severity of symptoms. The respondents included 
twenty mothers, four fathers and two aunts.  
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Table 1.  Age and Sickle Cell Disease Type for 26 Children Answering Follow-Up 
Questionnaire 
  Enrolled (n=26) 
          Age in years (range) 
Mean: 11 years (9 months to 18 
years) 
       Sickle Cell Disease Type  
                     HBSS 21 (84%) 
                     HB-SC 4 (16%) 
                     HB-SB+ 1 (4%) 
Sickle Cell Disease Severity  
No symptoms 0 (0%) 
Mild symptoms 12 (46%) 
Moderate symptoms 12 (46%) 
Severe symptoms 1 (4%) 
Not reported 1 (4%) 
 
Searched For More Information About Stem Cell Transplant   
Parents were asked if they had searched for more information (ex. Google, 
medical journal etc.) about stem cell transplant since their enrollment visit at Boston 
Medical Center. Of the twenty-six parents, six (23%) had searched for more information 
and twenty did not. Of the parents who had searched for more information, four had 
spoken to another person about stem cell transplant. Two considered their children to 
have mild disease and four considered their children to have moderate disease.  
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Table 2.  Parents Searched For More Information About Stem Cell Transplant  
Parent’s Answer Enrolled (n=26) 
Child’s Severity of 
Disease Considered By 
Parent 
Yes 6 (23%) 
Mild=2                                                                            
Moderate=4                                                                                                 
No 20 (77%) 
Mild=10                                                                             
Moderate=8                                             
Severe=1                                           
Missing=1 
 
 
 
Figure 4. Searched For More Information About Stem Cell Transplant  
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Recollection of Information                                                                                                            
Parents were asked if they remembered how often a full sibling is a genetic 
match. Of the twenty-six parents nine responded with the correct answer of less than half 
the time or 25% percent, seven responded 10%, six responded half the time and four 
responded more than half the time. Of the nine who answered correctly, one considered 
their child’s disease mild and seven considered their child’s disease moderate. Of the 
seven who responded 10%, four considered their child’s disease mild, two moderate and 
one severe. Of the six who responded 50%, four considered their child’s disease mild and 
two considered their child’s disease moderate. Of the four who answered severe, three 
considered their child’s disease mild and one moderate.       
Table 3. Recollection of Information About Stem Cell Transplant  
Parent’s Answer Enrolled (n=26) 
Child’s Severity of 
Disease Considered By 
Parent 
10% 7 (27%) 
Mild=4                                                                                       
Moderate=2                                                                     
Severe=1 
Less than half the 
time 
9 (35%) 
Mild=1                                                        
Moderate=7                                                                 
Missing=1 
Half the time 6 (23%) 
Mild=4                                                           
Moderate=2 
More than half the 
time 
4 (15%) 
Mild=3               
Moderate=1 
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Figure 5.  Recollection of Information  
 
 
 
Risk of Death Associated With Transplant 
        The risk of death that parents were willing to accept during the follow-up 
questionnaire ranged from 0 to 50% (Table 3). Of the twenty-six children thirteen were 
not willing to accept any risk, seven were able to accept 5% risk and three were able to 
accept a 10% risk. One was able to accept a 20% risk, and 2 were able to accept a 50% 
risk. Two of the three individuals willing to accept a 20% or 50% risk of death 
considered their children to have moderate sickle cell disease, had not spoken to anyone 
else for more information about stem cell transplant and were willing to accept the 
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procedure now. Six of the thirteen parents who weren’t able to consider any risk of death 
considered their child to have mild sickle cell disease, while six of the seven remaining 
parents considered their child to have moderate disease.  
 
Table 4.  Highest risk of death parents willing to accept from stem cell transplant   
Parent’s Answer Enrolled (n=26) 
Child’s Severity of 
Disease Considered By 
Parent 
0% 13 (50%) 
Mild=6                                                       
Moderate=6                                                            
Missing=1 
5% 7 (26.9%) 
Mild=4                         
Moderate=2                        
Severe=1 
10% 3 (11.5%) 
Mild=1                             
Moderate=2 
20% 1 (3.8%) Moderate=1 
50% 2 (7.6%) 
Mild=1 
  Moderate=1 
 
29 
 
Figure 6. Highest risk of death parents willing to accept from stem cell transplant  
 
 
Risk of Infertility Associated With Transplant  
The risk of infertility that parents were willing to accept ranged from 0 to 100% 
(Table 4). Of the twenty-six parents, three were not able to accept any risk of infertility, 
five accepted 5% risk and seven accepted 10% risk. One accepted 15% risk, two 20% 
risk and another two 25% risk. Two parents accepted 25% risk, another two 50% risk and 
four 100% risk. Two of the four parents willing to accept a100% infertility risk 
considered their child to have mild disease, while the other two believed their children to 
have moderate disease. Two of the three parents unable to accept any infertility risk 
considered their child’s disease to be moderate.  
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Table 5.  Highest risk of infertility parents willing to accept from stem cell 
transplant 
 
Parent’s Answer Enrolled (n=26) 
Child’s Severity of Disease 
Considered By Parent 
               0% 3 (11.5%) 
Moderate=2 
Missing=1 
5% 5 (19.2%) 
Mild=1                                                                                                                 
Moderate=3                                                                                                 
Severe=1 
10% 7 (26.9%) 
Mild=6 
Moderate=1 
15% 1 (3.8%) Moderate=1 
20% 2 (7.6%) 
Mild=1                                                                                                                           
Moderate=1 
25% 2 (7.6%) 
Mild=1                                                                                                                                   
Moderate=1 
50% 2 (7.6%) 
Mild=1 
Moderate=1 
100% 4 (15.3%) 
Mild=2                                                                                            
Moderate=2 
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 Figure 7.  Risk of Infertility Associated With Transplant  
 
 
 
Most Common Concern Associated With Transplant  
The second to last question in the follow-up questionnaire assessed what worried 
parents the most about the transplant procedure (Table 5). Of the twenty-six parents, nine 
worried most about death, while another nine worried most about the transplant not 
working. Two stated infertility, and one said graft-versus-host disease (GVHD). The 
remaining five parents were most worried about the recovery process after transplant. 
Three, however, spoke and searched for more information about transplant. These three 
parents were all willing to accept the offer of transplant and wanted to know more about 
its success rate.   
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Table 6.  Most common parental concern for stem cell transplant procedure  
 
Parent’s Answer Enrolled (n=26) 
Death 9 (34.6%) 
Transplant Not Working 9 (34.6%) 
Infertility 2 (7.6%) 
Graft-Versus-Host-Disease (GVHD) 1 (3.8%) 
Recovery Process After Transplant 5 (19.2%) 
 
 
Figure 8.  Most Common Concern Associated With Transplant  
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Hypothetical Scenario 
The last question on the follow-up questionnaire posed a hypothetical scenario in 
which a parent could choose transplant if the child’s sibling was a perfect match (Table 
6). Of the twenty-six parents, nineteen parents (73%) reported willingness to proceed to 
transplant and five (19%) reported they were not willing to accept the risk. The parents 
not willing to proceed to transplant had not spoken or searched for more information 
about stem cell transplant and considered their child’s sickle cell disease to be mild. Of 
the nineteen parents willing to proceed to transplant, ten believed their child’s disease to 
be mild, seven considered their child’s disease moderate and one believed her child’s 
disease to be severe.     
Table 7.  Hypothetical scenario in which parents could choose transplant if child’s 
sibling was a perfect match 
Parent’s Answer Enrolled (n=26) 
Child’s Severity of 
Disease Considered By 
Parent 
Yes 19 (73%) 
Mild=10                                                     
Moderate=7                                                               
Severe=1                                  
Missing=1    
 
No 5 (19%) 
Mild=1                                                   
Moderate=4 
Unable To Answer 2 (8%) 
Mild=1                                                         
Moderate=1 
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Figure 9.  Hypothetical Scenario  
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                                                           DISCUSSION  
This study, started in 2009, is the first to investigate what parents know about 
stem cell transplant, their opinions about the procedure, what they would like to know 
more about and the risks they are willing to accept for their child. It examines whether 
briefly educating parents influences their short or long-term perspectives about the 
procedure. This information is essential to physicians who may have patients with more 
severe sickle cell disease as well as social workers, hematologists or pediatricians who 
may serve as advocates for parents with children having sickle cell disease.  
Of the risks described to parents for transplant, infertility, isolation and death 
generated the most concern. Parents were willing to accept between 0 and 50% risk of 
death. Eleven of the twelve parents who considered their child’s disease to be mild stated 
mortality risks of 0, 5 or 10%. Two of the three parents who were willing to accept a 20 
or 50 percent risk considered their child’s disease moderate. These findings correlate with 
previous studies. For parents with SCD, one study found that only thirty-seven percent 
were unwilling to accept any risk of death, forty-six percent were able to accept a 15% 
mortality, and fifteen percent were willing to accept more than a 35% risk. Another study 
by Van Besien et al. 2010 indicated that sixty-two percent of adults with SCD were 
willing to accept more than a 10% risk and thirty percent of parents more than a thirty 
percent risk. These results demonstrate how as a child’s sickle cell disease progresses in 
severity, the parents’ willingness to accept death risk increases. Those living with sickle 
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cell disease are willing to accept more mortality risk. This finding may be present, 
because those with sickle cell disease have experience with potential complications.                                                               
Parents were willing to accept between a 0 to 100% risk of infertility. Seven of 
the thirteen parents who considered their child’s disease mild were willing to accept a 
10% or less risk of infertility. Four of the twelve parents who considered their child’s 
disease moderate were willing to accept a 25, 50 or 100% risk. These results indicate that 
as a child’s severity of disease increases, parents on average become more willing to 
accept a higher risk of infertility. Of the parents who considered their child’s disease 
mild, one was willing to accept a 25% risk and two a 100% risk. Therefore, the 
correlation between infertility risk and child’s severity of disease although present does 
not appear to be as strong as that between risk of death and disease severity.  
Although sickle cell disease has multiple risks, HSCT has been challenged as a 
treatment option due to limited donors. It is estimated that approximately eighteen 
percent of children will have a matched sibling donor (Wynn, 2009). Cord blood can be 
used as a source of stem cells for HSCT. Parents, however, have reported limited 
consideration of saving cord blood from past or future pregnancies (Boncimino, 2010). It 
is necessary for parents of children with severe sickle cell disease to consider transplant 
as it is the only treatment option. The study begun in 2009 and demonstrated that most 
parents (71%) considered it important to know if siblings were a match and 59% would 
consider having another child to find a donor. This positive attitude toward matched 
donors is reflected in the recollection of information in the follow-up questionnaire. The 
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most selected answer to the question of how often a full sibling is a match was the correct 
response of less than half the time. The two answers closest to less than half the time: 
10% and half the time each had seven and six parental responses, respectively. This result 
indicates how parents value matching donor information and thus are able to make a 
correct or close approximation. They reflect the importance of discussing HSCT and 
HLA typing as part of routine SCD care and teaching about transplant’s role as a 
potential curative option.  
Sickle cell anemia’s varied clinical course and phenotype make HSCT’s 
recommendation difficult. HSCT, however, has had much success in children of good 
health including no organ impairment and no chronic conditions (Bernaudin, 2005). 
Treatment has not had this success in the adult population (Abboud, 2009). Therefore, 
much focus has been on the interest and concerns of the parent population. To learn 
parents’ interest in HSCT and whether education prompted the search for more 
information, we asked parents in the follow-up questionnaire if they had looked for more 
information since their enrollment visit. Six of the parents stated that they had looked for 
more information while the remaining twenty stated that they did not. Although the 
majority of parents had not searched for more information, this finding may be due to 
parents’ lack of resources. This possibility would agree with what we found in the study 
begun in 2009. Forty percent of parents had not heard of HSCT, and fifty-eight percent 
did not believe there was any curative therapy for SCD.  After receiving a brief education 
about HSCT, sixty-seven percent agreed to consider transplant, and seventy-one percent 
38 
 
believed it was important to know if siblings were a match. These results indicate the 
importance of educating parents about HSCT, informing them that there is a potential 
cure for SCD and testing siblings to see if they are a match. It may be helpful to distribute 
information to patients to aid their long-term recollection.   
Parents of children with severe sickle cell disease were more aware of HSCT than 
those with asymptomatic or mild disease. Parents of children taking hydroxyurea were 
the least likely to know there was a curative option while those with children with 
moderate to severe disease were the most likely to know. These differences indicate 
physicians’ practice of discussing HSCT with only those who have more severe disease. 
It may be beneficial for health care providers to discuss transplant with parents in SCD’s 
early stages. This practice would allow parents to make fully informed decisions and 
consider transplant when it has the highest rate of success.  
The follow-up questionnaire assessed whether parents would consider transplant 
if given the knowledge and opportunity. Parents were asked if they would accept 
transplant for their child upon learning that the child’s sibling was a match. Nineteen 
agreed to accept transplant, five refused the option and two were unable to answer. Of the 
parents who agreed, ten considered their child to have mild disease, seven moderate and 
one severe. Of the parents who refused transplant, four considered their child’s disease 
moderate and one mild. These results highlight how parents of children with mild disease 
will consider transplant and are interested in understanding all their options. Physicians 
look at transplant as a “last resort” once the child has taken hydroxyurea and develops 
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complications. To target patients during their opportunity window, physicians may want 
to view transplant as a first-line treatment strategy to be discussed with all patients. The 
finding that one of the four parents who refused transplant considered their child’s 
disease mild and the other three moderate suggests that as SCD progresses, parents are 
more willing to consider alternative options. Physicians may introduce HSCT to all 
patients but emphasize this option more to those with severe disease.  
Hydroxyurea in addition to antibiotics and blood typing have prolonged the lives 
of those with SCD from fifty years ago. The life expectancy in America for those with 
SCD has risen from fourteen years in 1974 to fifty-three years in 2007 (Ender, 2011). 
Despite these treatments patients still live approximately thirty years less than the general 
African population. Fifty percent die by age fifty from stroke, organ failure, opioid-
seeking behavior and pregnancy complications (Marengo, 2007). It is unclear if parents 
are aware of this difference for their children. In the study begun in 2009, sixty-five 
percent of parents reported having another family member with SCD, and sixty-six 
percent reported fear for their child’s future. This fear may result from parents seeing 
relatives suffer due to pain crises, organ damage, gallstones or blindness. By 
understanding the potential future of their children with sickle cell disease, parents who 
consider their child’s disease mild may want to learn more about curative options and 
high-risk treatments. The majority of parents willing to accept transplant in each disease 
severity category indicates families’ openness to treatment options as opposed to a risk-
aversive response.  
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                                                                  APPENDIX 1 
                                                         Baseline Questionnaire 
Please answer the following questions to the best of your knowledge.  
1. What is the age of your child? ______ Years _____Months 
2. Does he have any siblings? ______ Yes _____No 
________ Number of siblings (same mother and father)  
________ Number of half-siblings (share one parent) 
3. What kind of sickle cell disease does your child have? (Please mark with an X) 
a) SS                                 c) SC                            e)  Not sure                     
b) S-B0 thal                       d) Other (please write in)_______  
 
4. What is the severity of your child’s sickle cell disease? 
a) No symptoms (ever) 
b) Mild  (infrequent symptoms that do not interfere with quality of life) 
c) Moderate  (frequent symptoms, but able participate in age appropriate activities) 
d) Severe  (frequent symptoms interfering with quality of life) 
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5. Has your child ever experienced any of the following conditions? (Check all that apply with 
an X): 
 No Yes Do 
not 
know 
Times/yea
r (past 
year) 
Total              
(approxi
mately) 
Pain episodes leading to visit to 
the emergency room or hospital 
     
Acute Chest Syndrome (Bad lung 
disease) 
     
Transient Ischaemic Event (TIA: 
short lasting change in 
consciousness or activity) 
     
Stroke (long lasting change in 
consciousness or activity) 
     
Abnormal neurologic study 
(transcranial Doppler or 
MRI/MRA) 
     
Osteonecrosis (thinning of the 
bone of the hip or shoulder) 
     
Priapism (spontaneous erection      
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of the penis) 
Antibodies against red cells for a 
blood transfusion. 
     
6. Has your child been treated with any of the following? (Check all that apply with an X) 
 No Yes  Do not know 
a) Hydroxyurea: a medicine 
for sickle cell disease 
   
b) Single blood transfusion    
c) Many blood transfusions 
(but not on a regular basis) 
   
d) Monthly blood 
transfusions 
   
e) Medicine to remove 
excess iron 
   
 
7. Is there a cure for sickle cell disease? (Please mark with an X) 
1. No____                                         2. Yes____ 
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8. Do you know any adults with sickle cell disease? (Please mark with an X) 
                              1. No____                                        2.  Yes____  
9. Have you ever heard about stem cell or bone marrow transplantation as a treatment option 
for sickle cell disease? (Please mark with an X) 
                               1.  No____                                         2. Yes____ 
10. Have you ever discussed or considered stem cell or bone marrow transplantation for your 
child? (Please mark with an X) 
                                 1. No____                                        2. Yes____ 
11. Would you be interested in learning about the role of stem cell transplant as treatment 
option in sickle cell disease? (Please mark with an X) 
1. No ____                                     2. Yes____ 
If you are not interested in learning more and would like to tell us why not, please write your 
reasons below (you do not have to write anything if you do not want to). 
 
 
 Informed Consent obtained _________  Study Number _________  Date _________ 
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                                        APPENDIX 2 
                                  Parent’s Perceptions Questionnaire 
Rate each the following questions from 1-5 with rising level of agreement with the 
statement.   
 1 
Dis-
agree 
2 
somewhat 
disagree 
3 
neutral 
4 
agree 
5 
strongly 
agree 
1. The information provided to 
me today about stem cell 
transplant was valuable. 
1 2 3 4 5 
2. I wish I had heard this 
information before. 
1 2 3 4 5 
3. I would consider stem cell 
transplant as a treatment 
option for my child any time. 
1 2 3 4 5 
4. I would consider stem cell 
transplant as a treatment 
option for my child only if his 
sickle cell disease worsens.  
1 2 3 4 5 
5. Knowing if my child has a 
“matched-sibling” that can 
serve as donor is important to 
me. 
1 2 3 4 5 
6. If my child does not have a 
“matched sibling” that can 
serve as donor, I would 
consider having another child 
to try again to find a donor. 
1 2 3 4 5 
7. If my child does not have a 
“matched sibling” that can 
serve as donor, I would 
consider using a donor from a 
bank. 
1 2 3 4 5 
8. I have saved the umbilical 
cord blood of my children in a 
1 2 3 4 5 
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bank (for use by my family). 
9. I have donated the umbilical 
cord of my children to a bank 
(for use by anyone who needs 
it).  
1 2 3 4 5 
10. I have considered saving 
the umbilical cord blood of my 
next child.  
1 2 3 4 5 
11. Seeing family members or 
friends with severe sickle cell 
disease makes me worry about 
my child’s health when he 
grows up. 
1 2 3 4 5 
12. Hearing the information 
about transplant has changed 
my mind in a positive way (now 
I feel interested in considering 
transplant). 
1 2 3 4 5 
13. Hearing the information 
about transplant has changed 
my mind in a negative way 
(now no longer would consider 
transplant).  
1 2 3 4 5 
14. The risks of transplant 
outweigh the benefit of a cure. 
1 2 3 4 5 
15. If your child had a sibling that could serve as donor, how strongly would you 
consider transplant? 
1. Not at all                                                                                                                                 
2. Somewhat strongly                                                                                       
3. Very strongly 
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16. How much do the following situations make you consider transplant? 
 1 
Not at 
all 
2 
Somewhat 
3 
A lot 
Frequency of pain episodes 1 2 3 
Need for pain killers (narcotics) 1 2 3 
Need for blood transfusions 1 2 3 
Worry about lung problems (acute chest 
syndrome) 
1 2 3 
Worry about increased risk for stroke 1 2 3 
Worry about increased risk for osteonecrosis 
(bone thinning) 
1 2 3 
Worry about increased risk for kidney 
problems 
1 2 3 
 
17. Among the risks of transplant explained to be today, I am most concerned 
about: 
(Rate in order of 1-7 with 1 being most important to you and 7 least important to 
you) 
 _____ Only achieving partial response (chimerism) 
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  _____ Graft versus host disease (donor cells attack the child’s skin, gut and/or 
liver) 
 _____ Need for isolation and restrictions (need to decrease contact with other for 
almost a year) 
 _____ Graft failure (transplant not working) 
_____ Risk of death (risk of dying from transplant related reasons) 
_____ Infertility (inability to have children after transplant) 
_____ Other: _________________________________________________ 
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